467 related articles for article (PubMed ID: 27563068)
21. WRAD: enabler of the SET1-family of H3K4 methyltransferases.
Ernst P; Vakoc CR
Brief Funct Genomics; 2012 May; 11(3):217-26. PubMed ID: 22652693
[TBL] [Abstract][Full Text] [Related]
22. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
[TBL] [Abstract][Full Text] [Related]
23. Hierarchical assembly of the MLL1 core complex regulates H3K4 methylation and is dependent on temperature and component concentration.
Namitz KEW; Tan S; Cosgrove MS
J Biol Chem; 2023 Feb; 299(2):102874. PubMed ID: 36623730
[TBL] [Abstract][Full Text] [Related]
24. Structural and biochemical insights into MLL1 core complex assembly.
Avdic V; Zhang P; Lanouette S; Groulx A; Tremblay V; Brunzelle J; Couture JF
Structure; 2011 Jan; 19(1):101-8. PubMed ID: 21220120
[TBL] [Abstract][Full Text] [Related]
25. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1/WDR5 complexes.
Wang Q; Yu M; Ma Y; Zhang X; Zhang H; Li S; Lan R; Lu F
Lab Invest; 2018 Dec; 98(12):1627-1641. PubMed ID: 30089852
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.
Senisterra G; Wu H; Allali-Hassani A; Wasney GA; Barsyte-Lovejoy D; Dombrovski L; Dong A; Nguyen KT; Smil D; Bolshan Y; Hajian T; He H; Seitova A; Chau I; Li F; Poda G; Couture JF; Brown PJ; Al-Awar R; Schapira M; Arrowsmith CH; Vedadi M
Biochem J; 2013 Jan; 449(1):151-9. PubMed ID: 22989411
[TBL] [Abstract][Full Text] [Related]
27. The internal interaction in RBBP5 regulates assembly and activity of MLL1 methyltransferase complex.
Han J; Li T; Li Y; Li M; Wang X; Peng C; Su C; Li N; Li Y; Xu Y; Chen Y
Nucleic Acids Res; 2019 Nov; 47(19):10426-10438. PubMed ID: 31544921
[TBL] [Abstract][Full Text] [Related]
28. Fine-tuning the stimulation of MLL1 methyltransferase activity by a histone H3-based peptide mimetic.
Avdic V; Zhang P; Lanouette S; Voronova A; Skerjanc I; Couture JF
FASEB J; 2011 Mar; 25(3):960-7. PubMed ID: 21135039
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
[TBL] [Abstract][Full Text] [Related]
31. Discovery of
Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
[TBL] [Abstract][Full Text] [Related]
33. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
35. Multistate structures of the MLL1-WRAD complex bound to H2B-ubiquitinated nucleosome.
Rahman S; Hoffmann NA; Worden EJ; Smith ML; Namitz KEW; Knutson BA; Cosgrove MS; Wolberger C
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2205691119. PubMed ID: 36095189
[TBL] [Abstract][Full Text] [Related]
36. Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex.
Ruthenburg AJ; Wang W; Graybosch DM; Li H; Allis CD; Patel DJ; Verdine GL
Nat Struct Mol Biol; 2006 Aug; 13(8):704-12. PubMed ID: 16829959
[TBL] [Abstract][Full Text] [Related]
37. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
[TBL] [Abstract][Full Text] [Related]
38. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1.
Odho Z; Southall SM; Wilson JR
J Biol Chem; 2010 Oct; 285(43):32967-32976. PubMed ID: 20716525
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
